W3C home > Mailing lists > Public > public-semweb-lifesci@w3.org > February 2011

Re: beefing up PharmaOntology Queries #Q6

From: Eric Prud'hommeaux <eric@w3.org>
Date: Fri, 18 Feb 2011 11:06:42 -0500
To: 'Christopher A Domarew' <chris@domarew.com>
Cc: public-semweb-lifesci@w3.org, 'Helena Deus' <helenadeus@gmail.com>
Message-ID: <20110218160640.GA13142@w3.org>
* 'Christopher A Domarew' <chris@domarew.com> [2011-02-15 11:36+0000]
> Eric, 
> 
> 	Here is one I found :   I can get you the full text if you need
> it.  Searching for more.  does this help?  C A phase 2 multiple
> ascending dose trial of bapineuzumab in mild to moderate Alzheimer
> disease.  AU Salloway S, Sperling R, Gilman S, Fox NC, Blennow K,
> Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R,
> Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman
> M,  SO Neurology. 2009;73(24):2061-70.    BACKGROUND: Bapineuzumab, a
> humanized anti-amyloid-beta (Abeta) monoclonal antibody for the
> potential treatment of Alzheimer disease (AD), was evaluated in a
> multiple ascending dose, safety, and efficacy study in mild to
> moderate AD. METHODS: The study enrolled 234 patients, randomly
> assigned to IV bapineuzumab or placebo in 4 dose cohorts (0.15, 0.5,
> 10, or 2.0 mg/kg). Patients received 6 infusions, 13 weeks apart,
> with final assessments at week 78. The prespecified primary efficacy
> analysis in the modified intent-to-treat population assumed linear
> decline and compared treatment differences within dose cohorts on the
> Alzheimer's Disease Assessment Scale-Cognitive and Disability
> Assessment for Dementia. Exploratory analyses combined dose cohorts
> and did not assume a specific pattern of decline. RESULTS: No
> significant differences were found in the primary efficacy analysis.
> Exploratory analyses showed potential treatment differences (p

Any LODD folks want to see if this is in LinkedCT? I tried and got nothing:
[[
eric@eric-ubu:~$ sparql -8 --service http://data.linkedct.org/sparql -e 'PREFIX linkedct: <http://data.linkedct.org/resource/linkedct/> PREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#> SELECT * { ?s rdfs:label ?o FILTER (REGEX(?o, "bapineuzumab", "i")) } limit 5'
┌────────────────────────────────────────────────────┬───────────────────────────────────────────────────────┐
│ ?o                                                 │ ?s                                                    │
│           "Intervention #1844 (Drug:Bapineuzumab)" │ <http://data.linkedct.org/resource/intervention/1844> │
│ "Intervention #1845 (Drug:Bapineuzumab (AAB-001))" │ <http://data.linkedct.org/resource/intervention/1845> │
└────────────────────────────────────────────────────┴───────────────────────────────────────────────────────┘
eric@eric-ubu:~$ sparql -8 --service http://data.linkedct.org/sparql -e 'PREFIX linkedct: <http://data.linkedct.org/resource/linkedct/> PREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#> SELECT * { <http://data.linkedct.org/resource/intervention/1844> ?p ?o }'
┌───────────────────────────────────────────────────────────┬────────────────────────────────────────────────────────────────┐
│ ?o                                                        │ ?p                                                             │
│                                            "Bapineuzumab" │ <http://data.linkedct.org/resource/linkedct/intervention_name> │
│                                                    "Drug" │ <http://data.linkedct.org/resource/linkedct/intervention_type> │
│                <http://dbpedia.org/resource/Bapineuzumab> │                 <http://www.w3.org/2000/01/rdf-schema#seeAlso> │
│                  "Intervention #1844 (Drug:Bapineuzumab)" │                   <http://www.w3.org/2000/01/rdf-schema#label> │
│                   <http://yago.org/resource/Bapineuzumab> │                 <http://www.w3.org/2000/01/rdf-schema#seeAlso> │
│                                                      1844 │   <http://data.linkedct.org/resource/linkedct/intervention_id> │
│ <http://data.linkedct.org/resource/linkedct/intervention> │              <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> │
└───────────────────────────────────────────────────────────┴────────────────────────────────────────────────────────────────┘
eric@eric-ubu:~$ sparql -8 --service http://data.linkedct.org/sparql -e 'PREFIX linkedct: <http://data.linkedct.org/resource/linkedct/> PREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#> SELECT * { ?s ?p <http://data.linkedct.org/resource/intervention/1844> }'
┌┐
││
└┘
eric@eric-ubu:~$ sparql -8 --service http://data.linkedct.org/sparql -e 'PREFIX linkedct: <http://data.linkedct.org/resource/linkedct/> SELECT * { ?s linkedct:criteria ?crit FILTER (regex(?crit, ".*APOE"))} limit 5'
]]

but I have no confidence that I did it right.
My goal is to be able to show this off at Wednesday's C-SHALS HCLS tutorial.


> Links:
> ------
> [1]
> http://www.w3.org/wiki/HCLSIG/PharmaOntology/Queries#Q6._Are_there_any_AD_patients_without_the_APOE4_allele_as_these_would_be_good_candidates_for_the_clinical_trial_involving_Bapineuzumab.3F
> 

-- 
-ericP
Received on Friday, 18 February 2011 16:07:17 GMT

This archive was generated by hypermail 2.3.1 : Tuesday, 26 March 2013 18:01:00 GMT